Sunitinib-induced hemoglobin changes are related to the dosing schedule

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1339-1340

  Van Der Veldt, Astrid A M ^a   Boven, Epie ^a   Vroling, Laura ^a   Broxterman, Henk J ^a   Van Den Eertwegh, Alfons J M ^a   Haanen, John G ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; NITRIC OXIDE; SUNITINIB; VASCULOTROPIN RECEPTOR 2;

DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTOSIS; HEMOGLOBIN DETERMINATION; HUMAN; KIDNEY CARCINOMA; LETTER; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HEMOGLOBINS; HUMANS; INDOLES; POLYCYTHEMIA; PYRROLES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 62449291582     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.6151     Document Type: Letter

References (10)

1. Alexandrescu DT, McClure R, Farzanmehr H, et al: Secondary erythrocy-tosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib. J Clin Oncol 26:4047-4048, 2008
2. Van der Veldt AA, Boven E, Helgason HH, et al: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer 99:259-265, 2008
3. Tarn BYY, Wei K, Rudge JS, et al: VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 12:793-800, 2006
4. Ebos JM, Lee CR, Christensen JG, et al: Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 104:17069-17074, 2007
5. Zhu X, Stergiopoulos K, Wu S: Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis. Acta Oncol 48:9-17, 2009
6. Mourad JJ, des Guetz G, Debbabi H, et al: Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 19:927-934, 2008
7. Van Heeckeren WJ, Ortiz J, Cooney MM, et al: Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: Clinical toxicity, therapeutic target, or novel biomarker? J Clin Oncol 25:2993-2995, 2007
8. Jin ZG, Ueba H, Tanimoto T, et al: Ligand-independent activation of vascular endothelial growth factor receptor 2 by fluid shear stress regulates activation of endothelial nitric oxide synthase. Circ Res 93:354-363, 2003
9. Van Cruijsen H, Van der Veldt AA, Hoekman K: Tyrosine kinase inhibitors of VEGF receptors: Clinical issues and remaining questions. Front Biosci 14:2248-2268, 2009
10. Filep JG: Endogenous endothelin modulates blood pressure, plasma volume, and albumin escape after systemic nitric oxide blockade. Hypertension 30:22-28, 1997